. . . continued from the previous page

A New Therapeutic Approach for Treating PARKINSON'S DISEASE

Footnotes:

1. CARLSSON A, LINDQUIST M, MAGNUSSON T et al. On the presence of 3- hydroxytyramine in brain. Science 1958: 137: 471-473
2. BIRKMAYER W, HORNYKIEWICZ O. Der L-Dioxyphenylalanin L-DOPA Effekt bei der Parkinson Akinese. Wr Klin Wschr 1961: 73: 787-793
3. LLOYD KG, DAVIDSON L, HORNYKIEWICZ O. The neurochemistry of Parkinson’s disease: effect of L-DOPA therapy. J Pharmacol Exp Ther 1975: 195: 453-464.
4. RIEDERER P, RAUSCH WD, BIRKMAYER W et al. CNS modulation and adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. Neural J Transm (Suppl.) 14: 121-131
5. BIRKMAYER W. Der alpha-methyl-p-Tyrosine Effekt bei extrapyramidalen Erkrankungen. Wr klin Wschr 1969: 81: 10-13.
6. Finch CE. The regulation of physiological changes during mammalian aging. Q Rev Biol 1976; 51: 49-83.
7. Algeri S, Calderini G, Lomuscio G, Toffano G, Ponzio F. Catecholamines and adaptive mechanisms in senescent rats. In: Corsini GU, Gessa, L, eds. Apomorphine and other Dopaminomimetics. Vol. 2, Clinical Pharmacology, New York, Raven Press, 1981; 2: 225-34.
8. McGeer EG, McGeer PL, Wada SA. Distribution of tyrosine hydroxylase in human and animal brain. J Neurochem 1971; 18: 1647-51.
9. Nies A, Robinson DS, Davis JM, Ravaris CL. Changes in monoamine oxidase with aging and depression in man. In: Eisdorfer C, Fann WE eds. Psychopharmacology and Aging: Advances in Behavioral Biology. New York: Plenum Press, 1973: 41-52.
10. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy of dopamine and 3-methosytyramine levels in human basal ganglia. J Neurol Transm 1976; 38: 271-301.
11. Gottfries CG, Gottfries L, Roos BE. Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and Parkinsonism. J Neurochem 1969; 16: 1341-5.
12. Gottfries CG. The metabolism of monoamines and their etiological importance in aging and in patients with dementia of Alzheimer type. In: Senile dementia: Outlook for the Future. New York: Alan R. Liss, Inc., 1984: 69-80.
13. Storga D, Vrecko K, Birkmayer JGD, Reibnegger G. Monoaminergic neurotransmitters in brains of morbus Alzheimer patients. Neurosci Lett (in print, 1966).
14. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics and therapy. Neurosci Res 1990; 27: 576-86.
15. Allard P, Alafuzoff I, Carlsson A. Eriksson K, Ericson E, Gottfries CG, Marcusson JO. Loss of dopamine uptake sites labeled with (3H) GBR-12935 in Alzheimer’s disease. European Neurol 1990; 30: 181-5.
16. Marcusson JO, Alafuzoff I, Bacstrom IT, Ericson E. Gottfries CG, Winblad B. 5-Hydroxytryptamine-sensitive 3 imipramine binding of protein nature in the human brain II, Effect of normal aging and dementia disorders. Brain Res 1987; 425: 137-45.
17. Pearce J. Mental changes in Parkinsonism. Brit. Med. J. Letter, 1974; 1: 445.

. . . back to the library